While Vir Biotech is best known for its work on infectious diseases, its developing cancer pipeline has delivered a partnership with Astellas that could be worth around $1.4 billion.
MOUNTAIN VIEW, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (RNXT) (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies, ...
A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, lowering the risk of death after eight years by 40.3%. What's more, the drug ...
Syndax Pharmaceuticals Inc. reports fourth-quarter results after the market close Thursday, with investors focused on whether the biotech’s recently launched cancer therapies can sustain commercial ...
Add Yahoo as a preferred source to see more of our stories on Google. A biologist works on DNA extracted from cancer tissue in Oncompass Medicine's laboratory in Budapest, Hungary, June 2, 2021.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results